Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Over the past two years, our team has delivered several operational improvements to get the business where it is today |
| But we did end the year in a really good position from a working capital perspective, as I mentioned on the call, which should be a little bit of upside to the $200 million that we previously disclosed |
| We definitely have more customers than we had last year, and where we see the slowdown is some of the specialists are just doing a little bit less than they were before, but we're confident that when the market returns, we're going to be in a really, really good place to grow faster |
| We invested to further differentiate our portfolio, which helped us make gains in the markets we serve |
| As well, we improved our operating efficiency through restructuring and cost-reduction initiatives |
| We believe we have quite elegantly addressed both of these concerns in one major move and now look very optimistically to 2024 as a pure-play Dental company with a comprehensive and industry-leading portfolio |
| Our team is immensely experienced in carving out and setting up new businesses, as well as improving the operational efficiency of businesses in transformation, and we are excited to employ these skills to position ZimVie for our next chapter |
| To reiterate, costs currently in continuing operations will be removed following the sale of Spine, allowing us to make market progress toward our desired margin profile |
| We are very pleased with our strategic position despite a challenging macro environment, and we expect that our comprehensive portfolio of premium implants, biomaterials, and digital dentistry and workflow solutions will continue to perform at or above market growth |
| We have been talking for a number of quarters now about our focus on driving better inventory management and reducing excess and obsolete inventory expenses, and are pleased that our efforts have translated to higher gross margins |
| We remain confident in delivering an adjusted EBITDA margin of over 15% one year post-Spine sale as previously disclosed |
| We expect improvement in cost of products sold in 2024 as we streamline the organization, cutting out duplicative cost, improving manufacturing efficiency, and benefit from a better product mix, particularly in the back half of the year |
| We appreciate your contributions and immense effort to improve the position of the business in the future and wish you great success going forward |
| As we transition through the sale of Spine, we are positioned to become a leaner, more focused, pure-play Dental company with market-leading position in the $8 billion implant digital solutions and biomaterials markets |
| While the dental market in aggregate was soft through most of '23, we are pleased to have exited the year roughly flat compared to 2022, a definitive sign that the strength of our Dental portfolio and ability to commercially execute in a challenging environment leaves us well-positioned for 2024 as market conditions begin to stabilize and improve |
| This includes innovative biomaterial products, which build a strong foundation for the implant and high-efficiency easy-to-use digital solutions for managing implant workflow |
| With a wholly focused management team and increased resources, we see room to grow that margin profile even further |
| Our Dental business has always enjoyed an attractive margin profile |
| So I do think that has been positive for us |
| But if you just simply take when we announced the deal, which was before the end of the year, and we said $200 million -- less $200 million of net debt, and then you actually take out where we ended, we ended actually in a much stronger cash position with almost $88 million, and we prepaid additional debt, that should be a little bit of upside that you could probably take into that net debt number |
| One of our top priorities for 2023 was to invest in this portfolio and we are pleased to continue our strong cadence of hardware and software innovations into 2024 |
| We are raising our expectations for annualized sales at one year post-Spine to over $455 million |
| We had significant accomplishments in 2023 |
| sales of $187.6 million was higher by 40 basis points and 30 basis points in reported and constant currency, respectively |
| We are committed to offering the market's highest quality premium implants and a holistic portfolio to support every step of the implant process |
| And the reason we've been able to hold it, the premium category, is primarily from two new implants that have been really, really effective, very, very sticky in the marketplace, coupled with a digital workflow, a guided solution workflow that is growing significantly faster than other digital platforms and faster than the rest of our business, now albeit it's a smaller base right now, but our entire thesis is predicated on that pulling through implants |
| Yes, we have benefited from some of the competitive dynamics in the market, and frankly, we've picked up some share there in a relatively slower market than we've experienced years prior |
| Our shared commitment spans our global sites as we work towards a common goal of establishing ZimVie's reputation as a good corporate citizen, as a destination workplace, and a true life sciences leader |
| We recognize the importance of innovation to our business and we realize that we have commercial momentum behind our offering |
| I'm excited about the prospects ahead of us and as always I look forward to updating you on the progress throughout the year |
| Statement |
|---|
| With regard to adjusted earnings per share, we expect Q1 to be depressed as a result of lower margin profile and increased relative burden of interest expense until the sale of Spine is complete |
| We believe this sale addresses two major concerns we have heard, the lack of synergy between Dental and Spine businesses and an overly leveraged capital structure during a time of elevated interest rates |
| In the U.S., fourth quarter 2023 third-party net sales of $81.5 million decreased by 10.3%, driven by continued competitive pressure |
| Full year OUS sales of $81.8 million declined by 11.4% in reported rates and 12.1% in constant currency |
| Beginning with continued operations, total third-party net sales for the fourth quarter of 2023 were $113.1 million, a decrease of 2.4% in reported rates and a decline of 3.6% in constant currency |
| third-party net sales of $18.9 million decreased by 11.6% on a reported basis and 12.0% in constant currency |
| In the U.S., third-party net sales for the fourth quarter of 2023 of $65.4 million decreased by 3.2%, driven by a slightly weaker implant market due to U.S |
| Total third-party net sales for the fourth quarter of 2023 were $100.5 million, a decrease of 10.6% on both a reported and constant currency basis |
| third-party net sales of $47.7 million decreased by 1.2% on a reported basis and 4.1% in constant currency |
| of $269.6 million represents a modest decline of 1.2%, driven by weaker implants as previously mentioned |
| sales of $327.3 million declined 8.4% |
| Full year 2023 total third-party net sales of $409.2 million represent a 9% decrease on a reported basis and 9.2% decrease in constant currency |
| The impact of foreign exchange on third-party net sales in 2023 was negligible, with constant currency sales declining 60 basis points versus 2022 |
| Given this classification, our continuing operations adjusted EBITDA margin for the fourth quarter and 2023 appears weighed down compared to our prior reporting framework |
| Full year 2023 total third-party net sales of $457.2 million were essentially flat year-over-year, declining 50 basis points |
| macroeconomic challenges, partially offset by strength in our digital solutions and biomaterials portfolio |
| I could not be more excited about the future of this company as we continue to invest and differentiate solutions for patients and providers while optimizing our structure to drive value for shareholders |
| Full year 2023 adjusted cost of products sold of 36.2% increased 40 basis points over the prior year of 35.8%, driven by slightly lower implant volume for the year |
| Full year 2023 adjusted cost of products sold at 27.2% decrease 180 basis points versus 29.0% in the prior year |
| So, Vafa, the number two in the implants market, they're facing some challenges in their domestic business, so I wanted to hear how you're thinking about that opportunity to either hire reps or capture share |
Please consider a small donation if you think this website provides you with relevant information